Literature DB >> 34712463

Incidence and prevalence of inflammatory bowel disease in Devon, UK.

Ben Hamilton1,2, Harry Green1,3, Neel Heerasing1, Peter Hendy1, Lucy Moore1, Neil Chanchlani1,2, Gareth Walker1,2, Claire Bewshea1, Nicholas A Kennedy1,2, Tariq Ahmad1,2, James Goodhand1,2.   

Abstract

BACKGROUND AND AIMS: We sought to define temporal changes in prevalence of inflammatory bowel disease (IBD) in East Devon, UK, in order to facilitate service planning over the next 5 years.
METHODS: Multiple primary and secondary care databases were used to identify and verify cases. Point prevalence and incidence of IBD were reported in April 2017 and from 2008 to 2016, respectively. Future prevalence and healthcare activity requirements were estimated by linear regression.
RESULTS: Prevalence of ulcerative colitis (UC), Crohn's disease (CD) and inflammatory bowel disease unclassified (IBDU) were 479.72, 265.94 and 35.34 per 100 000 persons, respectively. In 2016, the incidence rates of UC, CD and IBDU were 15.4, 10.7 and 1.4 per 100 000 persons per year, respectively. There were no significant changes in the incidence of CD (p=0.49, R=0.26) or UC (p=0.80, R=0.10). IBD prevalence has increased by 39.9% (95% CI 28.2 to 53.7) in the last 10 years without differences in the rate of change between UC and CD. Overall, 27% of patients were managed in primary care, a quarter of whom were eligible but not receiving endoscopic surveillance. Outpatient clinics, MRI and biologic use, but not helpline calls, admissions, or surgeries increased over and above the change in IBD prevalence.
CONCLUSIONS: We report one of the highest prevalence and incidence rates of IBD from Northern Europe. Overall, IBD incidence is static, but prevalence is increasing. We estimate that 1% of our population will live with IBD between 2025 and 2030. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  epidemiology; inflammatory bowel disease; primary care

Year:  2020        PMID: 34712463      PMCID: PMC8515282          DOI: 10.1136/flgastro-2019-101369

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  28 in total

1.  The use of models in the estimation of disease epidemiology.

Authors:  Michelle E Kruijshaar; Jan J Barendregt; Nancy Hoeymans
Journal:  Bull World Health Organ       Date:  2002-08-27       Impact factor: 9.408

2.  General practitioners' knowledge of and attitudes to inflammatory bowel disease.

Authors:  M Tan; R H Holloway; K Lange; J M Andrews
Journal:  Intern Med J       Date:  2012-07       Impact factor: 2.048

3.  A UK cost of care model for inflammatory bowel disease.

Authors:  Nivedita Ghosh; Purushothaman Premchand
Journal:  Frontline Gastroenterol       Date:  2015-02-24

4.  Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta-analysis.

Authors:  Yoon-Kyo An; David Prince; Fergus Gardiner; Teresa Neeman; Ecushla C Linedale; Jane M Andrews; Susan Connor; Jakob Begun
Journal:  Med J Aust       Date:  2019-11-03       Impact factor: 7.738

5.  Inflammatory bowel disease: epidemiology and management in an English general practice population.

Authors:  G P Rubin; A P Hungin; P J Kelly; J Ling
Journal:  Aliment Pharmacol Ther       Date:  2000-12       Impact factor: 8.171

6.  Mortality Risk of Inflammatory Bowel Disease: A Case-Control Study of New York State Death Records.

Authors:  Angelica Nocerino; Alexandra Feathers; Elena Ivanina; Laura Durbin; Arun Swaminath
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

7.  East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort.

Authors:  J Burisch; N Pedersen; S Čuković-Čavka; M Brinar; I Kaimakliotis; D Duricova; O Shonová; I Vind; S Avnstrøm; N Thorsgaard; V Andersen; S Krabbe; J F Dahlerup; R Salupere; K R Nielsen; J Olsen; P Manninen; P Collin; E V Tsianos; K H Katsanos; K Ladefoged; L Lakatos; E Björnsson; G Ragnarsson; Y Bailey; S Odes; D Schwartz; M Martinato; G Lupinacci; M Milla; A De Padova; R D'Incà; M Beltrami; L Kupcinskas; G Kiudelis; S Turcan; O Tighineanu; I Mihu; F Magro; L F Barros; A Goldis; D Lazar; E Belousova; I Nikulina; V Hernandez; D Martinez-Ares; S Almer; Y Zhulina; J Halfvarson; N Arebi; S Sebastian; P L Lakatos; E Langholz; P Munkholm
Journal:  Gut       Date:  2013-04-20       Impact factor: 23.059

8.  Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England.

Authors:  Margaret A Stone; John F Mayberry; Richard Baker
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-12       Impact factor: 2.566

9.  The Time Course of Diagnostic Delay in Inflammatory Bowel Disease Over the Last Sixty Years: An Italian Multicentre Study.

Authors:  Laura Cantoro; Antonio Di Sabatino; Claudio Papi; Giovanna Margagnoni; Sandro Ardizzone; Paolo Giuffrida; Diana Giannarelli; Alessandro Massari; Rita Monterubbianesi; Marco Vincenzo Lenti; Gino Roberto Corazza; Anna Kohn
Journal:  J Crohns Colitis       Date:  2017-08-01       Impact factor: 9.071

10.  IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology.

Authors:  Gareth-Rhys Jones; Mathew Lyons; Nikolas Plevris; Philip W Jenkinson; Cathy Bisset; Christopher Burgess; Shahida Din; James Fulforth; Paul Henderson; Gwo-Tzer Ho; Kathryn Kirkwood; Colin Noble; Alan G Shand; David C Wilson; Ian Dr Arnott; Charlie W Lees
Journal:  Gut       Date:  2019-07-11       Impact factor: 31.793

View more
  5 in total

Review 1.  The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease.

Authors:  Christopher A Lamb; Aamir Saifuddin; Nick Powell; Florian Rieder
Journal:  Gastroenterology       Date:  2022-01-04       Impact factor: 22.682

Review 2.  Pleiotropic Effects of Vitamin D in Patients with Inflammatory Bowel Diseases.

Authors:  Aleksandra Szymczak-Tomczak; Alicja Ewa Ratajczak; Marta Kaczmarek-Ryś; Szymon Hryhorowicz; Anna Maria Rychter; Agnieszka Zawada; Ryszard Słomski; Agnieszka Dobrowolska; Iwona Krela-Kaźmierczak
Journal:  J Clin Med       Date:  2022-09-27       Impact factor: 4.964

3.  Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?

Authors:  Simeng Lin; Neil Chanchlani; Isabel Carbery; Malik Janjua; Rachel Nice; Timothy J McDonald; Claire Bewshea; Nicholas A Kennedy; Tariq Ahmad; Christian P Selinger; James R Goodhand
Journal:  Aliment Pharmacol Ther       Date:  2022-06-29       Impact factor: 9.524

4.  Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patients.

Authors:  A Barney Hawthorne; Jackie Glatter; Jonathan Blackwell; Rachel Ainley; Ian Arnott; Kevin J Barrett; Graham Bell; Matthew J Brookes; Melissa Fletcher; Rafeeq Muhammed; Alan M Nevill; Jonathan Segal; Christian P Selinger; Anja St Clair Jones; Lisa Younge; Christopher A Lamb
Journal:  Aliment Pharmacol Ther       Date:  2022-06-01       Impact factor: 9.524

Review 5.  Current Use of EEN in Pre-Operative Optimisation in Crohn's Disease.

Authors:  Sharafaath Shariff; Gordon Moran; Caris Grimes; Rachel Margaret Cooney
Journal:  Nutrients       Date:  2021-12-08       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.